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Abstract
This paper discusses the physiological and technological concepts that might form the future of critical care
medicine. Initially, we discuss the need for a personalized approach and introduce the concept of personalized
physiological medicine (PPM), including (1) assessment of frailty and physiological reserve, (2) continuous
assessment of organ function, (3) assessment of the microcirculation and parenchymal cells, and (4) integration of
organ and cell function for continuous therapeutic feedback control. To understand the cellular basis of organ
failure, we discuss the processes that lead to cell death, including necrosis, necroptosis, autophagy, mitophagy, and
cellular senescence. In vivo technology is used to monitor these processes. To this end, we discuss new materials
for developing in vivo biosensors and drug delivery systems. Such in vivo biosensors will define the diagnostic
platform of the future ICU in vivo interacting with theragnostic drugs. In addition to pharmacological therapeutic
options, placement and control of artificial organs to support or replace failing organs will be central in the ICU in
vivo of the future. Remote monitoring and control of these biosensors and artificial organs will be made using
adaptive physiological mathematical modeling of the critically ill patient. The current state of these developments is
discussed.
Introduction
Personalized medicine for critically ill patients has
gained much interest in recent years, mainly as a re-
sponse to the lack of efficacy of randomized controlled
trials as a vehicle for improving the treatments and out-
comes in critically ill patients. Based on developments in
cancer research, personalized medicine has been
centered around genomics, biomarkers, and information
obtained from large data sets [1, 2]. We questioned
whether this approach was suited for critically ill
patients, because of the rapidly changing condition of
these patients and the complexity and heterogeneity of
the pathophysiology of critical illness. Thus, we sug-
gested that personalized medicine applied to critically ill
patients should focus on the physiological condition of
the patient integratively encompassing organ and cellular
systems, a concept we called “personalized physiological
medicine” (PPM) [3]. To this end, monitoring the direct
environment of the failing organ and its cellular constit-
uents continuously over time is necessary. Currently,
such monitoring involves intermittent sampling, usually
of surrogates of organ and cellular function; what is
needed for the future will be focused on the microcircu-
lation and the parenchymal level of the different organ
systems. The requirement of continuous monitoring at
the local level will require ex vivo diagnostic tools to be
located in vivo. This requirement also holds for thera-
peutic modalities to support organ function now located
ex vivo (e.g., mechanical ventilation, ECMO, and CVVH)
to be developed for in vivo use (e.g., cardiac assist de-
vices, artificial kidneys, and lungs). These concepts have
led to the identification of the requirements needed for
an ICU in vivo [4].
Personalized physiological medicine
A full understanding of the physiological state of the
critically ill patient requires an integrative functional
evaluation of the patient as a whole, from their organs
to their microcirculation and ultimately to the functional
activity of their parenchymal cells. A key feature for such
a diagnostic and therapeutic platform is the requirement
of providing continuous feedback regarding the func-
tional state of the various compartments being moni-
tored [5]. For such a PPM to be realized four main
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pillars can be defined (Fig. 1). Lack of fitness, the evalu-
ation of frailty, and physiological reserve define the first
pillar since these are directly related to cellular frailty
underlying organ dysfunction. The pandemic nature of
lack of fitness currently present in modern life-style is a
major contributing factor to morbidity and mortality [6],
and its identification and evaluation is important in un-
derstanding efficacy and prognostic impact of therapy
[7]. Muscle dysfunction and atrophy are directly related
to frailty and have been identified as important factors
underlying organ failure [8]. Recent insights into the im-
portance of exercise has identified muscle as being a key
hormone-generating organ, releasing a family of hor-
mones called myokines that are beneficial to a wide
range of physiological functions [9]. These insights have
opened a therapeutic window in terms of exercising
muscle in critically ill patients, possibly improving out-
comes [10]. The second pillar of PPM concerns the need
to continuously assess the function of each organ indi-
vidually as well as interactions among organs and with
physiological compartments within the various organ
systems to take into account the range and complexity
of disease states underlying critical illness. To achieve
this, technology will have to be developed and applied
for monitoring of physiological biomarkers in advance of
changes in pharmacological biomarkers as early indica-
tors of impending organ dysfunction [11]. From this per-
spective, every therapeutic intervention, whether it be
the administration of fluids, inotropes, or blood, is an
opportunity to evaluate the functional state and physio-
logical reserve of the various organ systems. Pillar three
concerns assessment of the microenvironment of the or-
gans, consisting of the microcirculation (oxygen and per-
fusion) and ultimately parenchymal function of the
organs in response to disease and therapy. A step toward
the realization of pillar 3 is the current interest in
hand-held vital microscopes (HVM) as bedside tools to
assess the microcirculation, providing complimentary in-
formation to conventional systemic variables concerning
the nature of critical illness [12]. HVM can also be used
effectively to evaluate microvascular reactivity and
physiological reserve [13]. Use of integrative evaluation
of various physiological variables to identify the state of
disease and response to therapy from organ to cell in
Fig. 1 The ICU in vivo: This conceptual figure shows the physiological and technological requirements of the anticipated future of the ICU, where
diagnostic devices and organ-assist devices now situated ex vivo will be transferred in vivo. Such an ICU in vivo will be based on personalized
physiological tracking and control of bodily, organ, and cellular functions in a continuous manner. These are based on the four pillars of
personalized physiological medicine (shown above) where assessment and (1) control of frailty and fitness, (2) organ function, (3) microcirculatory
and cellular function, and (4) integration of information of the patient as a whole into a learning environment to provide feedback control of
therapeutic modalities of the critically ill patient [3]. The technological components will have to be achieved to realize this concept of the ICU
in vivo
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vivo as well as control of implantable organ will require
placement of biosensors in vivo with wireless ex vivo
communication. Such information will need to be inte-
grated in mathematical models of the patient for
closed-loop control of therapeutic interventions. There-
fore, integration and feedback characterize pillar 4 in
much the same way as physiological homeostasis does.
The cell in distress
The ultimate success of the cardiovascular system to en-
sure parenchymal health in supporting organ function is
to ensure adequate delivery of oxygen and nutrients via
the microcirculation to parenchymal cells. Normal
physiological injury resulting in cell dysfunction is re-
solved by cell clearance and tissue repair. If injury is too
severe for the support of organ dysfunction by endogen-
ous rescue and repair mechanisms, critical care support
is indicated. In the ideal case, continuous information
regarding the functional state of the parenchymal cells
responsible for organ function should be available for
optimal therapeutic control. Since this is currently not
possible, such information is indirectly obtained by
intermittent assessment of surrogates of organ function
including pharmacological biomarkers of organ dysfunc-
tion. For rapidly changing systems such as those in crit-
ical illness, constraints are imposed by the Nyquist-
Shannon sampling theorem, whereby the variable re-
sponsible for control of a system has to be sampled at
least twice the highest rate of change of the system; this
requires, almost by definition, continuous monitoring
[14, 15]. Thus, if cellular dysfunction underlies organ
failure, monitoring biosensors would have to be devel-
oped in close proximity to the parenchymal cells of the
organ systems to obtain precise knowledge of the deter-
minants of cellular dysfunction in a continuous manner.
Nevertheless, knowledge concerning these determinants
needs to be acquired first. A discussion of the several
cellular processes being compromised as a result of in-
jury, however, is beyond the scope of this paper; never-
theless, a brief discussion of the cellular process leading
to cell death is relevant in context of the ICU in vivo.
Such information is needed to design accurate ICU in
vivo biosensors that are able to identify cellular frailty
and cells at risk for dying.
The best-known form of cell death is necrosis caused by
injury from external factors such as trauma, ischemia, and
infection. Necrosis results in a rapid permeabilization of
cell membranes so that cellular constituents spill into the
extracellular space. This causes inflammatory activation
that may fuel systemic inflammation or may contribute to
an adaptive response to resolve the deleterious effects of
necrosis [16]. Necroptosis is a programmed form of ne-
crosis that also leads to rapid cellular permeabilization,
spilling of cellular constituents, and damage-associated
molecular patterns eliciting an immune response [17, 18].
Such an immune response can elicit a storm of cytokines
that can, as in necrosis, itself cause tissue injury [19]. In
contrast to necrosis, apoptosis is a catabolic process where
cellular constituents are packaged into membranes called
apoptotic bodies and are phagocytosed by macrophages.
These apoptotic bodies are immunologically silent and
can be thought of as a physiological method of replenish-
ing dysfunctional cells and disposing of aged cells. Its acti-
vation is considered to be an important physiological
response associated with recovery from critical illness
[20, 21]. Programmed cell death of frail or injured cells
can also contribute to organ dysfunction. For example,
programmed cell death of red blood cells referred to as
eryptosis, precedes hemolysis, leading to release of free
Hb, causing parenchymal damage that contributes to
anemia and microcirculatory alterations [22]. Further-
more, endotoxin can lead to endothelial apoptosis
resulting in vascular barrier compromise that fuels
organ dysfunction [23].
Cell senescence is a different type of cell dysfunction
and is associated with frailty in old age and thought to
underlie a wide range of disease states, including critical
illness [24]. Cellular senescence has historically been
viewed as an irreversible cell-cycle arrest mechanism
that acts to protect against cancer [25]. However, in
aging, cell senescence is upregulated, thus contributing
to a decline in the ability of tissue repair and regener-
ation [26]. Such senescent cells have been referred to as
zombie cells and are currently under investigation as a
target for achieving longevity [27]. Its identification fits
well into the first pillar of PPM, namely, the identifica-
tion of frailty. Recent interest in cell cycle arrest bio-
markers as markers of the presence of acute kidney
injury (AKI) indicates the link between cell senescence
and organ failure [28]. Such biomarkers identify the
presence of senescent tubular cells that are thought to
contribute to the proliferation of non-functional fibro-
blasts resulting in fibrotic kidneys defining the progres-
sion of AKI to chronic kidney disease [29].
Endogenous mechanisms such as phagocytosis are
present for clearing apoptotic, necroptotic, and necrotic
cells, and these processes are central to ensuring health
and maintaining organ function following injury.
Autophagy is a programed mechanism for cell clearance
by the formation of autophagosomes and autolysosomes,
where intracellular compounds are degraded. In sepsis,
there is an initial upregulation of autophagy as defense
of the septic insult [30] but followed by downregulation
of cell apoptosis and its subforms such as mitophagy
may contribute to organ dysfunction [31–33]. The
current thinking is that knowledge of necrosis, apop-
tosis, and autophagy may be interactive in determining
the pathway that is most beneficial for survival [34].
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Therefore, it is expected that monitoring of necrosis,
necroptosis, senescence, and apoptosis will identify
whether a therapeutic strategy will lead to organ regen-
eration or if organ support or replacement by artificial
devices is warranted. Due to the spatial and temporal
heterogeneity of such cellular dysfunction, interactive
biosensors will be required to be close to parenchymal
cells in a continuous manner to provide information ne-
cessary to support clinical decisions and controlling drug
delivery and organ-assist devices. The understanding of
technology in the context of the above is viewed not
only as devices but to the whole continuum of external
from artificial hardware to biologics and any method-
ology used as a therapeutic intervention including drugs.
Theragnostics and biosensors for the ICU in vivo
The current diagnostic modalities lack the ability to pro-
vide continuous and quantitative information about spe-
cific organ locations. With regard to drug therapy, there
is a need for more precise homing of therapeutic drugs
and a need to know whether the drug has achieved its
delivery and accomplished its therapeutic action, an ap-
proach referred to as theragnostic drug delivery. Its
technological implementation, in which feedback is
given regarding arrival and therapeutic action, will re-
quire the development of new generations of nanoparti-
cles composed of homing devices, communication
modalities, and controlled mobility. Such nanoparticles
are currently mostly being developed in the field of on-
cology [35, 36]. New generations of materials are being
explored, including polymeric, gold, and silica for devel-
opment of theragnostic and biosensor platforms, includ-
ing the highly promising carbon nanotubes (CNT).
CNTs have unique electrical, physical, and chemical
properties particularly suited for the engineering re-
quirements of personalized nanomedicine [37, 38]. In
addition to these properties, they also possess specific
semiconductor properties that allow implementation of
electronics superior to those of conventional silicon-
based electronics [39, 40]. Biomolecules derived from
cells, bacteria, and viruses can also be incorporated into
the electronic environment of biosensors, an approach
referred to as synthetic biology [41]. In this way, engi-
neered bacteria can be used to home in on tumors and
emit signals when successfully reaching their target and
achieving their therapeutic actions [42].
Biosensors and drug delivery systems for the ICU in
vivo will require integration of biosensors, wireless com-
munication, and power sources. Such wireless biosensors
are currently under development for monitoring body
surfaces’ measurement of body fluid compositions [43].
Wireless control of nanomotors incorporating biosen-
sors is another field that is relevant for the ICU in vivo
[44]. Currently, mobile imaging biosensors have been in
clinical use, including wireless video capsules as an alter-
native to gastric endoscopy, where control of intragastric
movement and location can be achieved by external ap-
plication of magnetic fields [45]. It is not inconceivable
that nano-imaging modalities will be developed for fu-
ture intravascular imaging of the microcirculation and
their cells (Pillar 3 of PPM) in much the same way as
handheld vital microscopes are currently being used to
obtain cellular information about the microcirculation
[12].
Artificial organs in the ICU in vivo
Tissue engineering is a rapidly developing area, where
engineering, biology, and medicine are interacting to
make functional organs [46]. For identification of failed
cellular systems unable to support organ function and
cannot be therapeutically rescued, organs will either
have to be supported or replaced by artificial devices.
Currently, organ assist devices such as mechanical venti-
lation, ECMO, cardiac assist devices, and CVVH are ap-
plied ex vivo. However, in the ICU, in vivo artificial
organs will be placed in vivo for permanent support or
replacement. Current focus of the engineering of artifi-
cial organs and/or assist devices for failing hearts and
kidneys for in vivo integration are under development
(e.g., [47, 48]). Tissue engineering platforms under
current investigation include the use of organ extracellu-
lar matrixes [49, 50] and even 3D-printed organs [51].
These tissue-engineered organs and assist devices will re-
quire integration into normal physiology to achieve their
functional role in maintaining homeostasis. This will form
a major challenge for the ICU in vivo intensivist.
Feedback and integration in the ICU in vivo
The fourth pillar of PPM involves integration and feed-
back and is based on engineering concepts related to
control theory [52]. Linking mechanical ventilation to
ECMO in a closed-loop manner is a current example of
clinical implementation of feedback [53]. It is anticipated
that closed-loop systems for therapeutic and organ con-
trol will be central in the ICU in vivo. Wireless commu-
nication between sensor and effectors will be an
important pre-requisite for implementation of such
closed-loop systems in much the same way as is physio-
logically the case for homeostasis (Fig. 1). Signals from
biosensors in vivo could control theragnostic drug deliv-
ery and artificial organs. Such signals will generate a
massive amount of information and will need to be eval-
uated to extract essential parameters needed for control.
Such evaluation will require the use of mathematical
models of the various functional activities of organs and
parenchymal systems in an integrative and continuous
manner. Currently, such integrative modeling is being de-
veloped using a methodology referred to as computational
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physiology under the banner of the International Union of
Physiological Sciences [54]. This Physiome Project will
have to be extrapolated to model the critically ill patients,
taking into consideration their ever-changing condition,
and will require self-learning models, including artificial
intelligence such as being developed in various areas of
critical care medicine [55, 56]. It is expected that such a
virtual mathematical model of the individual patient will
be the platform whereby the intensivist will be able to
steer the patient from critical illness into recovery.
In conclusion, there are many challenges to be over-
won concerning the practical implementation of the
concepts discussed in this paper for the establishment of
the ICU in vivo. Most importantly, despite critical care
medicine being a multi disciplinarian science, much
more participation of disciplines outside intensive care
medicine is needed. This is especially a challenge for
physiologists who unfortunately, and I say this as a
physiologist, have shown a marginal interest in the
pathophysiology of intensive care medicine and have
chosen for a reductionist approach to pathophysiology
[57]. But also engineers who have limited themselves to
technical aspects of intensive care medicine should ex-
tend their interests into the clinical issues of complexity
of living systems and how these come under threat dur-
ing critical illness. And finally, the intensivists them-
selves must be even more willing to embrace new
technologies and concepts in moving intensive care
medicine forward instead of demanding yet another
RCT. Success will be guaranteed if the clinical, scientific,
and engineering community will come together to meet
this challenge for the future ICU in vivo.
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